Bristol-Myers Squibb

Bristol-Myers Squibb expands R&D in Massachusetts, cuts virology business

Friday, June 26, 2015 09:01 AM

Bristol-Myers Squibb has announced new steps in the evolution of the company's R&D organization, including plans to open a new state-of-the-art research site in Cambridge, Mass., in addition to the ongoing expansion of the company's R&D Discovery site in the San Francisco Bay Area.

More... »


PhRMA elects new members of board of directors

Monday, June 22, 2015 12:26 PM

The Pharmaceutical Research and Manufacturers of America (PhRMA) has announced the election of five of its newest members to its board of directors.

More... »


Report: Pharma R&D pipeline value jumps 18% to $493 billion

Wednesday, June 17, 2015 10:32 AM

Emerging therapeutic categories and a string of breakthrough drug approvals are powering key drug sales across the U.S. and Europe, fueling a projected 5% increase in global prescription sales over the next five years, according to the EvaluatePharma World Preview 2015, Outlook to 2020 report from life science market intelligence firm Evaluate. With the FDA approving an unprecedented 50 drugs in 2014, eight of which are forecast to have sales of more than $1 billion five years after launch, sustained R&D productivity may finally be within reach.

More... »

Fosun Pharma, HOPU Investments, CEL Healthcare Fund, WuXi PharmaTech to acquire Ambrx

Friday, May 22, 2015 01:50 PM

A consortium—consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU InvestmentsChina Everbright’s Healthcare Fund and WuXi PharmaTech—has signed a merger agreement to acquire Ambrx. The transaction is expected to close in the second quarter of 2015, subject to receipt of certain regulatory approvals and satisfaction of customary closing conditions.

More... »

Safe-Biopharma launches cyber security consulting service for life science, healthcare

Friday, April 24, 2015 01:18 PM

SAFE-BioPharma Association has created SBP Digital Trust Consulting, a resource of internationally recognized identity and access management (IAM) policy and technical experts for life science and healthcare companies seeking to develop improved cyber security strategies.

More... »

Incyte joins Safe-Biopharma Association

Friday, April 17, 2015 12:39 PM

Incyte, a Delaware-based biopharmaceutical company, has joined SAFE-BioPharma Association, a nonprofit industry coalition responsible for the ongoing development and implementation of the SAFE-BioPharma digital identity and signature standard.

More... »

Bristol-Myers Squibb, uniQure collaborate on gene therapies for cardiovascular diseases

Wednesday, April 8, 2015 01:03 PM

Bristol-Myers Squibb has inked an agreement with uniQure, a gene therapy developer based in the Netherlands, for exclusive access to uniQure’s gene therapy technology platform for multiple targets in cardiovascular diseases.

More... »

FDA expands approved use of Opdivo to treat lung cancer

Thursday, March 5, 2015 01:42 PM

The FDA has expanded the approved use of Opdivo (nivolumab) to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.

More... »

Bristol-Myers Squibb, Bavarian Nordic ink agreement for PROSTVAC

Wednesday, March 4, 2015 01:06 PM

Bristol-Myers Squibb has signed an exclusive option to license and commercialize PROSTVAC, Bavarian Nordic's investigational phase III prostate-specific antigen (PSA)-targeting cancer immunotherapy in development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).

More... »

Bristol-Myers Squibb to acquire Flexus Biosciences

Monday, February 23, 2015 01:02 PM

Bristol-Myers Squibb has signed a definitive agreement to acquire all of the outstanding capital stock of Flexus Biosciences, a San Carlos, Calif.-based, privately held biotech focused on the discovery and development of novel anti-cancer therapeutics. The transaction has a potential total consideration of $1.25 billion, including $800 million upfront and development milestones that, upon achievement, could total up to $450 million. The transaction has been approved by the boards of directors of both companies and by the stockholders of Flexus.

More... »


CWWeekly

July 6

FDA sued by advocacy groups seeking hepatitis C trials data

Google to test health-tracking wristband to collect clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs